Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients

Abstract

Arschang Valipour,1 Michael Tamm,2 Jana Kociánová,3 Valentina Bayer,4 Maria Sanzharovskaya,5 Alexey Medvedchikov,6 Monika Haaksma-Herczegh,6 János Mucsi,7 Zvi Fridlender,8 Claudia Toma,9,10 Andrey Belevskiy,11 Bohumil Matula,12 Jurij Šorli13 1Department of Respiratory and Critical Care Medicine, Karl-Landsteiner-Institute for Lung Research and Pulmonary Oncology, Krankenhaus Nord – Klinik Floridsdorf, Vienna, Austria; 2Lung Centre/Pneumology Department, University Hospital Basel, Basel, Switzerland; 3Pneumological Outpatient Department, MephaCentrum, a.s., Ostrava-Poruba, Czech Republic; 4Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 5Respiratory TA, Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria; 6Medical Affairs Regional Center, Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria; 7Elizabeth Nursing Home, Gödöllő, Hungary; 8Department of Internal Medicine, Hebrew University Hadassah Medical School, Jerusalem, Israel; 9Department of Pneumology, Institute of Pneumatology “Marius Nasta”, Bucharest, Romania; 10Department Of Pneumology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; 11Department of Pulmonology, Pirogov Russian National Research Medical University, Pletnev Hospital, Moscow, Russian Federation; 12Department of Functional Diagnostics, Specialized Hospital of Saint Zoerardus, Teaching Facility of the Slovak Medical University, Nitra, Slovakia; 13Topolšica Hospital, Topolšica, SloveniaCorrespondence: Arschang ValipourDepartment of Respiratory and Critical Care Medicine, Karl-Landsteiner-Institute for Lung Research and Pulmonary Oncology, Krankenhaus Nord-Klinik, Floridsdorf Brünnerstrasse 68, Wien, Vienna 1210, AustriaTel [phone]Email [email protected]: Reduced physical activity is associated with increased morbidity and mortality in patients with COPD. Studies suggest that treatment with the long-acting muscarinic antagonist tiotropium and the long-acting β2-agonist olodaterol increases exercise capacity. This study assessed the effects of a fixed-dose combination (FDC) of tiotropium/olodaterol (delivered via Respimat®) on physical functioning in patients with stable COPD in a “real-world setting”.Methods: An international, open-label, single-arm, non-interventional study conducted in nine countries measuring changes in self-reported physical functioning in COPD patients treated with tiotropium/olodaterol 5/5 μg FDC for approximately 6 weeks. The primary endpoint was therapeutic success, defined as a minimum 10-point increase in the 10-question Physical Functioning Questionnaire (PF-10) score. Secondary endpoints included absolute change in PF-10 from Visit 1 to Visit 2, patient general condition (measured by Physician’s Global Evaluation score) and patient satisfaction with the treatment and device (assessed by Patient Satisfaction Questionnaire at the end of the study period).Results: Therapeutic success was observed in 67.8% of 7218 patients (95% CI 66.7, 68.8) in the final analysis set after approximately 6 weeks of treatment with tiotropium/olodaterol. Mean change in PF-10 score between Visit 1 and Visit 2 was 16.6 points (95% CI 16.2, 17.0). Therapeutic success was 64.3% (95% CI 63.0–65.6%) in patients with infrequent (≤1) and 76.1% (95% CI 74.3–77.9%) in patients with frequent (≥2) exacerbations (p<0.0001). Patient general condition improved as indicated by an improvement in Physician’s Global Evaluation scores between visits. Most patients were very satisfied or satisfied with tiotropium/olodaterol treatment in general (81%), reported inhalation satisfaction (85%), and satisfactory handling of the device (84%). 1.3% of patients reported an investigator-defined drug-related adverse event.Conclusion: Treatment with tiotropium/olodaterol led to an improvement in self-reported physical functioning in patients with COPD.Keywords: tiotropium, olodaterol, chronic obstructive pulmonary disease, COPD, physical functioning, non-interventional study

Keywords

• Tiotropium
• olodaterol
• chronic obstructive pulmonary disease
• COPD
• physical functioning
• non-interventional study